Good clinical practice recommendations in allergen immunotherapy: Position paper of the Brazilian Association of Allergy and Immunology – ASBAI

Is allergen immunotherapy a model of personalized treatment in pediatric respiratory allergy?

“…The optimal duration time for AIT is three to five years after initiating the maintenance phase. AIT should be maintained for at least three years to achieve lasting efficacy [14–16,17 ▪▪ ,18–20].…”

“…These approaches are gaining global popularity as they facilitate quicker clinical control of allergic diseases. Although the chance of local and systemic adverse reactions is more likely with these accelerated SCIT regimens, their clinical management is akin to the conventional approach [15,20].…”

“…For SCIT, dosing must be individually determined with up-dosing to achieve a maintenance dose that is both well tolerated and within the probable effective range [14][15][16]17 && , [19][20][21]. Standard initial dilutions from the concentrate are typically 1 : 10 000 (vol/vol) or 1 : 1000 (vol/vol).…”

“…The monthly cumulative SLIT dose varies significantly compared to that of the subcutaneous route, ranging from 0.017 to over 500 times greater. However, these variations have been found effective across different daily SLIT allergen dosages (<5 mcg/ day, 5 to <20 mcg/day, and >20 mcg/day) [15]. It is vital that SLIT-tablet dosing adheres to prescription labels.…”

“…The optimal duration time for AIT is three to five years after initiating the maintenance phase. AIT should be maintained for at least three years to achieve lasting efficacy [14][15][16]17 && ,18-20]. Currently, SCIT and SLIT are considered effective and safe forms of treatment for respiratory allergies in children and have been approved by the European Medicine Agency (EMA) and Food and Drug Administration (FDA).…”